Timolol, a β-adrenergic blocking agent, recently became available for the treatment of
glaucoma. We report the occurrence of acute bronchospasm in a previously asymptomatic …

A patient with glaucoma simplex and chronic pulmonary obstruction was treated with the
non‐selective β‐adrenergic blocking agent timolol in ophthalmic solution of 0.25% for 1 1/2 …

We studied cardiovascular effects related to ophthalmic timolol maleate, a beta-adrenergic
blocker commonly used to treat chronic glaucoma. Twenty normal subjects were randomly …

• Timolol maleate, a β-adrenergic blocking agent, was used in a study of 20 adult patients
with chronic open-angle glaucoma. This single-dose study demonstrated a dose response …

The propensity of systemic beta-adrenergic blockers to cause bronchoconstriction in
patients with reactive airway disease is well recognized. A study was carried out to …

Timolol maleate is the first β-adrenergic—blocking drug available in the United States for
topical therapy in open angle glaucoma. It may be used alone for initial therapy in selected …

The literature concerning the clinical and pharmacologic studies of systemically
administered timolol in 2233 patients was reviewed. Side effects reported were correlated …

• Timolol maleate, a β-adrenergic blocking agent, was studied in 30 patients With glaucoma.
Significant intraocular pressure lowering was achieved with 0.5% and 1.5% solution of the …

The interaction of oral and topical timolol maleate was studied in patients with open-angle
glaucoma. The oral and topical preparations given separately produced a significant and …

We treated 20 patients who had primary open-angle glaucoma with either 0.25% or 0.5%
timolol for nine weeks. Once-daily administration of timolol significantly reduced intraocular …